HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Wave Life Sciences USA, Inc.

Contributing Author

Recent Articles by Wave Life Sciences USA, Inc.

Jan-12
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio WVE GlobeNewswire
Jan-05
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference WVE GlobeNewswire
Dec-09
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants WVE GlobeNewswire
Dec-08
Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants WVE GlobeNewswire
Dec-08
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss WVE GlobeNewswire
Dec-07
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 WVE GlobeNewswire
Nov-10
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update WVE GlobeNewswire
Nov-07
Wave Life Sciences to Present at Upcoming Investor Conferences WVE GlobeNewswire
Nov-04
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek 2025 WVE GlobeNewswire
Nov-04
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025 WVE GlobeNewswire
Oct-29
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day WVE GlobeNewswire
Oct-29
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day WVE GlobeNewswire
Sep-18
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences WVE GlobeNewswire
Sep-03
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency WVE GlobeNewswire
Jul-30
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE GlobeNewswire
Jul-23
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025 WVE GlobeNewswire
Jun-20
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions WVE GlobeNewswire
May-29
Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference WVE GlobeNewswire
May-28
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer WVE GlobeNewswire
May-08
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update WVE GlobeNewswire
May-01
Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025 WVE GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.